Drugs / DAT-1604
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06998173 | Jul 2025 → Dec 2026 expected | cancer | Danatlas Pharmaceuticals Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAT-1604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998173 ↗ |
| Action | Inhibit | “small molecule inhibitor of DNA Polymerase θ (Pol θ)” NCT06998173 ↗ |
| Modality | Small molecule | “oral small molecule inhibitor” NCT06998173 ↗ |
| Route | Oral | “administered orally” NCT06998173 ↗ |